Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369555 | 0.87 | MAPK8 (0.47) | MAPK8MAPK10MAPK14MAP2K4MAPT | |
| SCHEMBL6370071 | 0.87 | MAP2K4 (0.46) | MAPK8MAPK10MAPK14MAP2K4MAPT | |
| SCHEMBL6370068 | 0.87 | MAP2K4 (0.48) | MAPK10MAPK14MAP2K4MAPTSMN1; SMN2 | |
| SCHEMBL6370428 | 0.85 | MAP2K4 (0.47) | MAP2K4MAPTSMN1; SMN2TP53POLB | |
| SCHEMBL6375165 | 0.84 | PTGER1 (0.51) | MAP2K4MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6370211 | 0.82 | MAP2K4 (0.44) | MAP2K4SMN1; SMN2TP53GAALMNA | |
| SCHEMBL6370616 | 0.82 | MAP2K4 (0.57) | MAP2K4MAPTPTGDR2PTGER1JAK2 | |
| SCHEMBL6378102 | 0.81 | MAPK8 (0.46) | MAPK8MAPK10MAPK14MAP2K4SMN1; SMN2 | |
| SCHEMBL6369989 | 0.81 | MAP2K4 (0.43) | MAPK14MAP2K4MAPTSMN1; SMN2GAA | |
| SCHEMBL6375104 | 0.80 | MAP2K4 (0.58) | MAP2K4MAPTTP53POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAPK8 1582/4885MAPK10 2059/4885MAPK14 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.